TheTechno Optimist.

PROSPR (Proactive Solutions for Prolonging Resilience)ARPA-H—VITAL-H trial begins at University of Texas Health Science Center, largest PROSPR award at $38MARPA-H—Likarda-led team gets up to $7.3M from ARPA-H to keep cell therapies stable at room temperaturePROSPR (Proactive Solutions for Prolonging Resilience)ARPA-H—ARPA-H awards $144M to seven teams for PROSPR aging research program

ARPA-H

PROSPR aging program, $144M, US government research

USpublicest. 2022arpa-h.gov (opens arpa-h.gov)Checked 10 Oct

The brief

Analyst view
  • ARPA-H established by Congress March 2022, housed in NIH; director reports to HHS Secretary.
  • PROSPR funds 7 teams to test rapamycin, SGLT2i, semaglutide and other drugs for aging.
  • Establishes FDA pathways for aging as a medical condition, removing a key geroscience bottleneck.

Technical approach

As reported
Biomarkers

Early actionable aging biomarkers

Identify biomarkers responding to aging interventions, creating FDA approval pathways.

Drug repurposing

Test FDA-approved drugs for aging

Rapamycin, SGLT2 inhibitors, semaglutide; skips 10+ years of new drug development.

Speed design

Phase 3 hybrid trials (3-5 years)

Longitudinal data and responsive biomarkers accelerate results vs traditional aging research.

Primer